Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites

Open access
Yang, Chun, Yang, Jianjun, Luo, Ailin, Hashimoto, Kenji · 2019 · Translational Psychiatry

Abstract

Although the robust antidepressant effects of the N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown. NMDAR inhibition and the subsequent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation are suggested to play a role in the antidepressant effects of ketamine. Although (R)-ketamine is a less potent NMDAR antagonist than (S)-ketamine, (R)-ketamine has shown more marked and longer-lasting antidepressant-like effects than (S)-ketamine in several animal models of depression. Furthermore, non-ketamine NMDAR antagonists do not exhibit robust ketamine-like antidepressant effects in patients with depression. These findings suggest that mechanisms other than NMDAR inhibition play a key role in the antidepressant effects of ketamine. Duman’s group demonstrated that the activation of mammalian target of rapamycin complex 1 (mTORC1) in the medial prefrontal cortex is reportedly involved in the antidepressant effects of ketamine. However, we reported that mTORC1 serves a role in the antidepressant effects of (S)-ketamine, but not of (R)-ketamine, and that extracellular signal-regulated kinase possibly underlie the antidepressant effects of (R)-ketamine. Several lines of evidence have demonstrated that brain-derived neurotrophic factor (BDNF) and its receptor, tyrosine kinase receptor B (TrkB), are crucial in the antidepressant effects of ketamine and its two enantiomers, (R)-ketamine and (S)-ketamine, in rodents. In addition, (2 R,6 R)-hydroxynormetamine [a metabolite of (R)-ketamine] and (S)-norketamine [a metabolite of (S)-ketamine] have been shown to exhibit antidepressant-like effects on rodents through the BDNF–TrkB cascade. In this review, we discuss recent findings on the molecular and cellular mechanisms underlying the antidepressant effects of enantiomers of ketamine and its metabolites. It may be time to reconsider the hypothesis of NMDAR inhibition and the subsequent AMPAR activation in the antidepressant effects of ketamine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-019-0624-1

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Chemical structure of enantiomers of ketamine and its metabolites. (R)-ketamine [or (S)-ketamine] is initially metabolized to (R)-norketamine [or (S)-norketamine] by either CYP2B6 or CYP3A4, and then metabolized to (R)-dehydronorketamine (DHNK) [or (S)-DHNK]. Hydroxylation of (R)-norketamine [or (S)-norketamine] at the sixth position by CYP2A6 results in (2R,6R)-hydroxynorketamine (HNK) [or (2S,6S)-HNK]. (R)-ketamine [or (S)-ketamine] is also metabolized to (2R,6R)-hydroxyketamine (HK) [or (2S,6S)-HK], then to (2R,6R)-HNK [or (2S,6S)-HNK]49. The values in the parenthesis are the Ki value for the NMDAR37,41
Fig. 1 Chemical structure of enantiomers of ketamine and its metabolites. (R)-ketamine [or (S)-ketamine] is initially metabolized to (R)-norketamine [or (S)-norketamine] by either CYP2B6 or CYP3A4, and then metabolized to (R)-dehydronorketamine (DHNK) [or (S)-DHNK]. Hydroxylation of (R)-norketamine [or (S)-norketamine] at the sixth position by CYP2A6 results in (2R,6R)-hydroxynorketamine (HNK) [or (2S,6S)-HNK]. (R)-ketamine [or (S)-ketamine] is also metabolized to (2R,6R)-hydroxyketamine (HK) [or (2S,6S)-HK], then to (2R,6R)-HNK [or (2S,6S)-HNK]49. The values in the parenthesis are the Ki value for the NMDAR37,41CC BY · PubMed Central
Fig. 2 Proposed cellular mechanisms of antidepressant actions of enantiomers of ketamine, and its metabolites. Left: (S)-Ketamine is metabolized to (S)-norketamine. (S)-Ketamine activate AMPAR, subsequently, (S)-ketamine activates mTORC1 signaling, resulting in activation of BDNF–TrkB signaling40,72. Although (S)-norketamine does not activate AMPAR, (S)-norketamine activates mTORC1 signaling, resulting in activation of BDNF–TrkB signaling119. Right: (R)-Ketamine is metabolized to (2R,6R)-HNK. Antidepressant-like effects of (R)-ketamine in rodents are more potent than (S)-ketamine, and antidepressant-like effects of (2R,6R)-HNK are inconsistent. (R)-Ketamine activates AMPAR, subsequently, (R)-ketamine might activate MEK–ERK signaling, resulting in activation of BDNF–TrkB signaling40,72. AMPAR activation may be necessary for antidepressant-like actions of (2R,6R)-HNK41. The mTORC1 signaling and BDNF-TrkB signaling may play a role in the antidepressant effects of (R)-ketamine40,72
Fig. 2 Proposed cellular mechanisms of antidepressant actions of enantiomers of ketamine, and its metabolites. Left: (S)-Ketamine is metabolized to (S)-norketamine. (S)-Ketamine activate AMPAR, subsequently, (S)-ketamine activates mTORC1 signaling, resulting in activation of BDNF–TrkB signaling40,72. Although (S)-norketamine does not activate AMPAR, (S)-norketamine activates mTORC1 signaling, resulting in activation of BDNF–TrkB signaling119. Right: (R)-Ketamine is metabolized to (2R,6R)-HNK. Antidepressant-like effects of (R)-ketamine in rodents are more potent than (S)-ketamine, and antidepressant-like effects of (2R,6R)-HNK are inconsistent. (R)-Ketamine activates AMPAR, subsequently, (R)-ketamine might activate MEK–ERK signaling, resulting in activation of BDNF–TrkB signaling40,72. AMPAR activation may be necessary for antidepressant-like actions of (2R,6R)-HNK41. The mTORC1 signaling and BDNF-TrkB signaling may play a role in the antidepressant effects of (R)-ketamine40,72CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 136 references

Cited by

See all 199

Metadata

Authors
Yang, C., Yang, J., Luo, A., & Hashimoto, K.
Affiliations
  • Jiangsu Province Hospital (CN)
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Tongji Hospital (CN)
  • Chiba University (JP)
Corresponding author
Hashimoto, Kenji
Venue
Translational Psychiatry
Published
2019-11-07
Volume
9
Issue
1
Pages
280-280
ISSN
2158-3188 (ISSN-L)
OpenAlex
W2986257172
Cited by
190
References
136
Citations by year
2026: 11 · 2025: 17 · 2024: 24 · 2023: 28 · 2022: 34 · 2021: 38 · 2020: 34 · 2019: 4
FWCI
3.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Natural Science Foundation of China (1703482, 81771159, 81571047)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
ketamine, ketamine enantiomers, antidepressant mechanism, treatment-resistant depression, NMDA receptor antagonism, mTORC1, medial prefrontal cortex, ERK, BDNF/TrkB signaling, ketamine metabolites
MeSH terms
Animals, Antidepressive Agents, Depression, Disease Models, Animal, Hippocampus, Humans, Ketamine, Stress, Psychological, Receptors, N-Methyl-D-Aspartate, Prefrontal Cortex, Receptors, AMPA, Brain-Derived Neurotrophic Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. https://app.cochat.ai/papers/10.1038/s41398-019-0624-1
The paper
Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019). Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Translational Psychiatry. https://doi.org/10.1038/s41398-019-0624-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.